-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Reiterates Overweight on Cytek Biosciences, Maintains $6 Price Target

Benzinga·03/19/2025 14:07:32
Listen to the news
Stephens & Co. analyst Mason Carrico reiterates Cytek Biosciences (NASDAQ:CTKB) with a Overweight and maintains $6 price target.